Logo image of XGN

EXAGEN INC (XGN) Stock Overview

NASDAQ:XGN - US30068X1037 - Common Stock

9.61 USD
-0.25 (-2.54%)
Last: 9/2/2025, 4:10:11 PM
9.61 USD
0 (0%)
After Hours: 9/2/2025, 4:10:11 PM

XGN Key Statistics, Chart & Performance

Key Statistics
52 Week High10.34
52 Week Low2.38
Market Cap211.42M
Shares22.00M
Float15.12M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.86
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10/bmo
IPO09-19 2019-09-19
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


XGN short term performance overview.The bars show the price performance of XGN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 50 100 150

XGN long term performance overview.The bars show the price performance of XGN in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200 250

The current stock price of XGN is 9.61 USD. In the past month the price increased by 14.25%. In the past year, price increased by 230.87%.

EXAGEN INC / XGN Daily stock chart

XGN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.01 374.37B
AMGN AMGEN INC 13.16 154.47B
GILD GILEAD SCIENCES INC 14.56 139.85B
VRTX VERTEX PHARMACEUTICALS INC 23.67 102.81B
REGN REGENERON PHARMACEUTICALS 12.66 61.25B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.59B
ARGX ARGENX SE - ADR 76.2 43.23B
ONC BEONE MEDICINES LTD-ADR 6.68 39.47B
INSM INSMED INC N/A 30.71B
BNTX BIONTECH SE-ADR N/A 24.19B
NTRA NATERA INC N/A 23.24B
BIIB BIOGEN INC 8.72 20.47B

About XGN

Company Profile

XGN logo image Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company is headquartered in Vista, California and currently employs 203 full-time employees. The company went IPO on 2019-09-19. The firm is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.

Company Info

EXAGEN INC

1261 Liberty Way

Vista CALIFORNIA 92081 US

CEO: Fortunato Ron Rocca

Employees: 212

XGN Company Website

XGN Investor Relations

Phone: 17605601501

EXAGEN INC / XGN FAQ

What is the stock price of EXAGEN INC today?

The current stock price of XGN is 9.61 USD. The price decreased by -2.54% in the last trading session.


What is the ticker symbol for EXAGEN INC stock?

The exchange symbol of EXAGEN INC is XGN and it is listed on the Nasdaq exchange.


On which exchange is XGN stock listed?

XGN stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for EXAGEN INC stock?

11 analysts have analysed XGN and the average price target is 11.39 USD. This implies a price increase of 18.52% is expected in the next year compared to the current price of 9.61. Check the EXAGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is EXAGEN INC worth?

EXAGEN INC (XGN) has a market capitalization of 211.42M USD. This makes XGN a Micro Cap stock.


How many employees does EXAGEN INC have?

EXAGEN INC (XGN) currently has 212 employees.


What are the support and resistance levels for EXAGEN INC (XGN) stock?

EXAGEN INC (XGN) has a support level at 9.54. Check the full technical report for a detailed analysis of XGN support and resistance levels.


Is EXAGEN INC (XGN) expected to grow?

The Revenue of EXAGEN INC (XGN) is expected to grow by 20.67% in the next year. Check the estimates tab for more information on the XGN EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy EXAGEN INC (XGN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does EXAGEN INC (XGN) stock pay dividends?

XGN does not pay a dividend.


When does EXAGEN INC (XGN) report earnings?

EXAGEN INC (XGN) will report earnings on 2025-11-10, before the market open.


What is the Price/Earnings (PE) ratio of EXAGEN INC (XGN)?

EXAGEN INC (XGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.86).


What is the Short Interest ratio of EXAGEN INC (XGN) stock?

The outstanding short interest for EXAGEN INC (XGN) is 3.65% of its float. Check the ownership tab for more information on the XGN short interest.


XGN Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to XGN. When comparing the yearly performance of all stocks, XGN is one of the better performing stocks in the market, outperforming 97.81% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

XGN Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to XGN. Both the profitability and financial health of XGN have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

XGN Financial Highlights

Over the last trailing twelve months XGN reported a non-GAAP Earnings per Share(EPS) of -0.86. The EPS increased by 11.75% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -28.9%
ROE -80.73%
Debt/Equity 1.06
Chartmill High Growth Momentum
EPS Q2Q%-10%
Sales Q2Q%14.19%
EPS 1Y (TTM)11.75%
Revenue 1Y (TTM)3.89%

XGN Forecast & Estimates

11 analysts have analysed XGN and the average price target is 11.39 USD. This implies a price increase of 18.52% is expected in the next year compared to the current price of 9.61.

For the next year, analysts expect an EPS growth of 16.04% and a revenue growth 20.67% for XGN


Analysts
Analysts83.64
Price Target11.39 (18.52%)
EPS Next Y16.04%
Revenue Next Year20.67%

XGN Ownership

Ownership
Inst Owners38.73%
Ins Owners7.74%
Short Float %3.65%
Short Ratio1.75